Literature DB >> 24604061

Biocatalytic polymer thin films: optimization of the multilayered architecture towards in situ synthesis of anti-proliferative drugs.

Sidsel Ø Andreasen1, Betina Fejerskov, Alexander N Zelikin.   

Abstract

We report on the assembly of multi-layered polyelectrolyte thin films containing an immobilized enzyme to perform conversion of externally administered prodrugs and achieve delivery of the resulting therapeutics to adhering cells. Towards this goal, multi-layered coatings were assembled using poly(sodium styrene sulfonate) and poly(allylamine hydrochloride). Activity of the incorporated enzyme was quantified as a function of the assembly conditions, position of the enzyme within the multi-layered architecture, concentration of the enzyme in the adsorption solution, and concentration of the administered prodrug. Biocatalytic coatings exhibited sustained levels of enzymatic activity over at least one week of incubation in physiological buffers without signs of loss of activity of the enzyme. Developed enzyme-containing polymer films afforded zero-order release of the in situ synthesized cargo with kinetics of synthesis (nM per hour) covering at least 3 orders of magnitude. Internalization of the synthesized product by adhering cells was visualized using a fluorogenic enzyme substrate. Therapeutic utility of biocatalytic coatings was demonstrated using a myoblast cell line and a prodrug for the anti-proliferative agent, 5-fluorouridine. Taken together, this work presents a novel approach to delivery of small molecule drugs using multi-layered polymer thin films with utility in surface-mediated drug delivery, assembly of therapeutic implantable devices, and tissue engineering.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24604061     DOI: 10.1039/c3nr05999e

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  6 in total

1.  Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics.

Authors:  Rona Chandrawati; Morten T J Olesen; Thatiane C C Marini; Gurpal Bisra; Anne Géraldine Guex; Marcelo G de Oliveira; Alexander N Zelikin; Molly M Stevens
Journal:  Adv Healthc Mater       Date:  2017-07-12       Impact factor: 9.933

2.  Enzyme Prodrug Therapy Achieves Site-Specific, Personalized Physiological Responses to the Locally Produced Nitric Oxide.

Authors:  Anna K Winther; Betina Fejerskov; Marja Ter Meer; Najah B S Jensen; Ross Dillion; Jeremy E Schaffer; Rona Chandrawati; Molly M Stevens; Leo J Schultze Kool; Ulf Simonsen; Alexander N Zelikin
Journal:  ACS Appl Mater Interfaces       Date:  2018-03-23       Impact factor: 9.229

3.  Biotransporting Biocatalytic Reactors toward Therapeutic Nanofactories.

Authors:  Tomoki Nishimura; Kazunari Akiyoshi
Journal:  Adv Sci (Weinh)       Date:  2018-09-19       Impact factor: 16.806

4.  Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma.

Authors:  Rona Chandrawati; Jason Y H Chang; Ester Reina-Torres; Coline Jumeaux; Joseph M Sherwood; W Daniel Stamer; Alexander N Zelikin; Darryl R Overby; Molly M Stevens
Journal:  Adv Mater       Date:  2017-02-21       Impact factor: 30.849

5.  Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy.

Authors:  Gregor Fuhrmann; Rona Chandrawati; Paresh A Parmar; Timothy J Keane; Stephanie A Maynard; Sergio Bertazzo; Molly M Stevens
Journal:  Adv Mater       Date:  2018-02-23       Impact factor: 30.849

6.  Combatting implant-associated biofilms through localized drug synthesis.

Authors:  Raoul Walther; Signe Maria Nielsen; Rikke Christiansen; Rikke L Meyer; Alexander N Zelikin
Journal:  J Control Release       Date:  2018-08-20       Impact factor: 9.776

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.